D.A. Davidson & CO. Has $2.84 Million Holdings in Guardant Health, Inc. $GH

D.A. Davidson & CO. lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 72.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,718 shares of the company’s stock after acquiring an additional 12,866 shares during the quarter. D.A. Davidson & CO.’s holdings in Guardant Health were worth $2,837,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after acquiring an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares during the period. Franklin Resources Inc. boosted its position in Guardant Health by 14.9% during the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after purchasing an additional 435,232 shares during the period. Geode Capital Management LLC grew its holdings in Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after purchasing an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in Guardant Health by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after purchasing an additional 72,162 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $155.87 on Monday. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $174.08. The firm has a market capitalization of $20.67 billion, a price-to-earnings ratio of -45.98 and a beta of 1.59. The stock’s 50-day moving average price is $134.21 and its 200 day moving average price is $110.33.

Insider Buying and Selling

In related news, CFO Michael Brian Bell sold 2,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the completion of the transaction, the chief financial officer directly owned 47,509 shares in the company, valued at approximately $6,110,607.58. This represents a 4.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Myrtle S. Potter sold 1,556 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $204,084.96. Following the completion of the transaction, the director directly owned 20,971 shares of the company’s stock, valued at approximately $2,750,556.36. This trade represents a 6.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 708,565 shares of company stock worth $90,556,597. 5.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GH. Royal Bank Of Canada assumed coverage on shares of Guardant Health in a research note on Thursday, June 11th. They issued an “outperform” rating and a $185.00 price objective for the company. Morgan Stanley raised their target price on shares of Guardant Health from $130.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Guggenheim lifted their target price on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday. Bank of America boosted their target price on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Finally, TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $160.04.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.